Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Grass Pollen Allergy-Pipeline Review, H2 2016

Grass Pollen Allergy-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Grass Pollen Allergy-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Grass Pollen Allergy-Pipeline Review, H2 2016', provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy

The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects

The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Grass Pollen Allergy Overview 6

Therapeutics Development 7

Pipeline Products for Grass Pollen Allergy-Overview 7

Grass Pollen Allergy-Therapeutics under Development by Companies 8

Grass Pollen Allergy-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Grass Pollen Allergy-Products under Development by Companies 11

Grass Pollen Allergy-Companies Involved in Therapeutics Development 12

ALK-Abello A/S 12

Allergy Therapeutics Plc 13

Biomay AG 14

Circassia Pharmaceuticals Plc 15

HAL Allergy BV 16

Roxall Medizin GmbH 17

Shionogi & Co., Ltd. 18

Grass Pollen Allergy-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

asapiprant-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BM-32-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

clustoid wiesenlieschgras-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Pollinex Quattro Grass-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

standardized grass pollen [timothy (Phleum pratense)] allergen extract-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Grass Pollen Allergy-Dormant Projects 42

Grass Pollen Allergy-Product Development Milestones 43

Featured News & Press Releases 43

Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204 43

Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children 43

May 25, 2016: Circassia Initiates Grass Allergy Immunotherapy Registration Study 45

Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 46

Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32 47

Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children 47

Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. 48

Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 49

Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 49

Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 50

Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 51

Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 51

Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 51

Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 52

Nov 09, 2013: Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Figures

Number of Products under Development for Grass Pollen Allergy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

List of Tables

Number of Products under Development for Grass Pollen Allergy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Grass Pollen Allergy-Pipeline by ALK-Abello A/S, H2 2016 12

Grass Pollen Allergy-Pipeline by Allergy Therapeutics Plc, H2 2016 13

Grass Pollen Allergy-Pipeline by Biomay AG, H2 2016 14

Grass Pollen Allergy-Pipeline by Circassia Pharmaceuticals Plc, H2 2016 15

Grass Pollen Allergy-Pipeline by HAL Allergy BV, H2 2016 16

Grass Pollen Allergy-Pipeline by Roxall Medizin GmbH, H2 2016 17

Grass Pollen Allergy-Pipeline by Shionogi & Co., Ltd., H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Grass Pollen Allergy-Dormant Projects, H2 2016 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ALK-Abello A/S

Allergy Therapeutics Plc

Biomay AG

Circassia Pharmaceuticals Plc

HAL Allergy BV

Roxall Medizin GmbH

Shionogi & Co., Ltd.

Grass Pollen Allergy Therapeutic Products under Development, Key Players in Grass Pollen Allergy Therapeutics, Grass Pollen Allergy Pipeline Overview, Grass Pollen Allergy Pipeline, Grass Pollen Allergy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com